![]() Second, T cells from the sample are separated and activated. ![]() First, the patient's white blood cells (those involved in disease-fighting) are collected. By engineering T cells to become smarter at recognizing (and attacking) a patient's cancer cells, Kite's biotechnology can potentially deliver the silver bullets for many seemingly hopeless cancer patients.Īs a personalized medicine, ETCs therapeutic is engineered in various steps. In contrast to other diseases, cancers are quite adept at evading attacks by the immune system via evolving their cellular targets. Similar to "the general" of an army, the thymus ("T") cells are key intelligence units of the body's defense system (coined the immune system), that direct the combating of diseases like cancer. That being said, we'll walk readers through the complexity of Kite's engineered T cells therapies ("CAR-TCR"). For most development-stage biopharma firms, the alluded intrinsic values resides in the efficacy and safety of its therapeutics (as indicated by the drugs' mechanism of action and trial data results). ![]() So that leaves us with the task of assessing Kite's true worth. "Oracle of Omaha" Warren Buffett stated that, while share price tends to fluctuate in the short term, it will almost always match the intrinsic value of a company in the long term. As the winds of fortunes - illustrative of the corporate developments and promising early trial results - have enabled the stock to soar by more than 200% in the past four years, the elephant in the room is whether Kite will continue its flight trajectory. To increase the chances of ETCs success, Kite partnered with Alpine Immunes Sciences in 2015 for the access to its Transmembrane Immunomodulatory Protein ("TIP") that, in and of itself, enhances the functioning of ETCs. This biotechnology can potentially deliver the biggest cancer treatment breakthrough since the introduction of chemotherapy more than half a century ago. With the dramatic results seen thus far in early clinical trials (and especially the cancer remission witnessed in refractory cases), the firm has reasons to pride itself as the leader in ETCs. Talk about room for ROI! Especially considering the Kite got $11.9B for only one mRNA patent and didnt even have one FDA clearance! We have two:Īnd they are both being Reactivated if Koos can beat the buyout:įirst Offical Reddit Post.Based in Santa Monica, California, Kite Pharma ( NASDAQ: KITE) is dedicated to the delivery of cancer therapeutics through the innovative engineered T cell therapy ("ETCs") platform. I trust those who want to can find those!Īnd, yes, its true, our IP was progressed with offical collaborations from Eli Lilly along the way:Ĭurrent Regen Market cap of about $80M. There are many more Patents listed still with USPTO. Now put the last two links together in your mind. This confirms the IP Regen owns with NR2F6. Then may I suggest you research the newest patent activity list in this $RGBP 8K: So this above Government Publication strongly confirms the significance of NR2F6. gov publication specifically on it 8 days ago: ![]() Not only every potentially reactive molecule/compounds(part of Eli Lilly Work), but Regen also patented the way to test and discover more activity with NR2F6. So What does Regen own? In a nutshell: Just about every aspect of Nuclear Cell Receptor NR2F6. Not only that but advanced IP! With INDs. With Todays undeniable focus on attaining mRNA advances by the big boys, I honestly cant find a better mRNA IP equiped company. Not trying to turn this into to anything but cliff notes. Santosh Kesari, Eli Lilly and Company, Oregon State University. The Working IP and Collaborative History of Regen is Undeniable: Dr. Thousands of Lab hours behind Regen, and Big Pharmas pay Big bucks for cutting edge advances which offer them cutting edges in lab time. As-Is! With the two INDs reactivated(or their ownership rights transfered as part of $20B) That number is repeatedly been offered to me in a strictly scientific research and Intellectual value. Regen Biopharma will either raise(or has raised) enough capital to solve its clerical issues(which it is obviously in progress of) and fund carrying the mRNA therapies it has locked up to market, or Regen is bought out by Big Pharma: Truly only one of two possible scenarios. $RGBP $RBGPP Details: ✅ $19m in Debt ✅ 2 FDA Cleared IND ✅ 20+ #mRNA Patents #NR2F6 ✅ Massive Global mRNA Focus Kite Pharma Details: ⭕️ $500m in Debt ⭕️ 0 FDA Cleared IND ⭕️ 1 #mRNA Patent ⭕️ No mRNA Attention
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |